8-K - Phio Pharmaceuticals Corp. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Phio Pharmaceuticals Corp. entered into the Second Amendment to the Employment Agreement of President and CEO Robert J. Bitterman on February 17, 2026. The amendment increases his annual target bonus opportunity to 50% of base salary from 40% and extends severance to 12 months of base salary upon termination without cause or for good reason.

Key Takeaways

1Second Amendment to Employment Agreement executed February 17, 2026

2Robert J. Bitterman, President and CEO

3Annual target bonus increased to 50% of base salary from 40%

4Severance provision amended to 12 months base salary

5Applies to termination without cause or for good reason

6Filed as Exhibit 10.1

Current Report Details

Event Type

Management Change

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

5.02

(d). Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On Februa

Management Change

9.01

. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Second Amendment to the Employment Agreement of Robert J. Bitterman, dated Februa

Exhibits Only

Executive & Director Changes

Robert J. Bitterman

President and Chief Executive Officer

Compensatory Arrangement Amendment

Effective: 2026-02-17

Exhibits (2)

10.1

EXHIBIT 10.1

8-K

FORM 8-K